大和:升药明生物(02269.HK)目标价至35.5港元 RDM各环节强劲增长

智通财经
Aug 21, 2025
【大和:升药明生物(02269.HK)目标价至35.5港元 RDM各环节强劲增长】智通财经APP获悉,大和发布研报称,药明生物(02269.HK)2025年上半年业绩符合预期,收入、毛利率及积压订单均实现强劲增长,研发-开发-生产(RDM)各环节在2025年下半年能见度高,毛利率预计持续改善,该行重申“买入”评级。针对2025至2027年预测,将毛利率预测上调1.5至1.6个百分点,并将销售及管理费用预测下调7%,以反映2025年上半年最新趋势。因此,将2025至2027年每股盈利预测上调3%至10%,目标价由30港元上调至35.5港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10